RxDoctor Payments Data

Gautam Patankar, MD

Cardiovascular Disease · Houston, TXNPI 1497071203

Payments from drug & device makers

$2,819in general payments, 2019–2025

Across 146 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$355
  • Merck$313
  • Tactile Systems Technology Inc$280
  • Boston Scientific$236
  • Abbott$224
  • E.r. Squibb & Sons, L.L.C.$183
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,79599%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,819 in reported general payments places this provider in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$1,156,981
Medicare patients
1,399
Services billed
5,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$182,050
EntrestoSacubitril/Valsartan49$64,903
XareltoRivaroxaban48$53,557
BrilintaTicagrelor19$19,093
FarxigaDapagliflozin Propanediol14$15,705
OzempicSemaglutide14$15,089
VascepaIcosapent Ethyl14$10,826
Metoprolol Succinate211$2,962
Rosuvastatin Calcium186$2,700
Ezetimibe91$2,165
Atorvastatin Calcium242$2,148
Nifedipine ErNifedipine73$1,914
ClopidogrelClopidogrel Bisulfate206$1,837
Amiodarone Hcl71$1,827
Flecainide Acetate34$1,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$81$182,050180 claims
NovartisEntresto$140$64,90349 claims
Johnson & JohnsonXarelto$99$53,55748 claims
AstraZenecaBrilinta, Farxiga$92$34,79833 claims
Novo NordiskOzempic$23$15,08914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →